JAMA Dermatology Publishes Phase 3 VALOR Trial Results for Brepocitinib in Dermatomyositis

Recent publications detail skin-specific outcomes from the Phase 3 VALOR clinical trial, demonstrating the efficacy of brepocitinib in treating dermatomyositis.